HP-α-CD Clathrates Modulate Phosphoinositide Cycle
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases and malignancies, such as Alzheimer's, Parkinson's, and breast cancer, often have undesirable side effects and fail to effectively regulate endocytosis and lysosomal dysfunction, which are common underlying factors in these conditions.
Innovation Solution
The use of alpha-cyclodextrins, particularly hydroxypropyl-alpha-cyclodextrin (HP-α-CD), which form clathrates with medium chain fatty acids, to target and modulate the phosphoinositide cycle, thereby regulating endocytosis and improving autophagy, reducing lysosomal stress, and treating diseases involving impaired lysosomal function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If beta-cyclodextrins are used to treat neurodegenerative diseases and malignancies, then therapeutic effect is improved, but ototoxicity occurs
Solution Approach 1:
The patent changes the chemical structure parameter of cyclodextrin from beta to alpha configuration, and further modifies it by adding hydroxypropyl groups. This parameter change transforms the molecule's properties: it maintains the ability to treat neurodegenerative diseases and malignancies while eliminating the ototoxic side effect associated with beta-cyclodextrins
Solution Approach 2:
The hydroxypropyl-alpha-cyclodextrin acts as an intermediary compound that mediates between the therapeutic needs (treating neurodegenerative diseases and cancers) and the safety concern (avoiding ototoxicity). It provides the beneficial effects of cyclodextrins while avoiding their harmful effects through its modified molecular structure
2Ease of operation
If current treatments for neurodegenerative diseases are used, then symptom management is achieved, but underlying lysosomal dysfunction and endocytosis regulation are not addressed
Solution Approach 1:
The patent extracts and addresses the root cause of neurodegenerative diseases by specifically targeting lysosomal dysfunction and endocytosis regulation. Instead of merely managing symptoms, the hydroxypropyl-alpha-cyclodextrin intervention extracts and corrects the underlying pathological mechanism, thereby controlling disease progression more effectively
Solution Approach 2:
The treatment addresses lysosomal dysfunction and endocytosis regulation before these defects lead to severe neurological damage. By intervening at the level of fundamental cellular processes, the therapy performs preliminary action that prevents disease progression rather than merely responding to established symptoms
3Reliability
If conventional cancer treatments (chemotherapy, radiation) are used, then tumor growth is inhibited, but substantial side effects occur
Solution Approach 1:
The patent employs a fundamentally different therapeutic parameter - using modified cyclodextrins with specific molecular characteristics to treat cancer. This parameter change shifts the treatment mechanism from direct cytotoxicity (chemotherapy/radiation) to modulation of cellular uptake and lysosomal function, achieving tumor growth inhibition with substantially reduced side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
HP-α-CD effectively treats conditions like breast cancer, Alzheimer's, and Parkinson's by improving autophagy and reducing lysosomal stress without causing ototoxicity, offering a more efficient and safer alternative to beta-cyclodextrins.
Implementation Method 1
The use of alpha-cyclodextrins, particularly hydroxypropyl-alpha-cyclodextrin (HP-α-CD), which form clathrates with medium chain fatty acids
Data Source
AI summary
In some embodiments, the present disclosure provides certain compositions and methods that may be useful in the treatment and/or prevention of malignant, neurodegenerative, vascular, metabolic, inflammatory, autoimmune, pulmonary, fibrotic, hepatic, lysosomal storage, or viral disease, disorder, or condition, such as carcinomas, Alzheimer's and Parkinson's disease, multiple sclerosis, Paget's disease, or other aspects of aging, such as atherosclerosis or type-2 diabetes. In some such embodiments, compositions are provided that contain at least one cyclodextrin active agent, such as alpha-cyclodextrin, or an analogue or derivative thereof. In some embodiments, the composition is a clathrate of hydroxypropyl-alpha-cyclodextrin and sodium caprate.